Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. This phase II trial is studying how well vorinostat works in treating patients with
locally recurrent or metastatic cancer of the urothelium.